Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Alembic Pharmaceuticals - US continues to be under pressure - ICICI Securities

Posted On: 2021-05-05 04:53:06 (Time Zone: UTC)


Alembic Pharma (Alembic) reported Q4FY21 performance largely in line with estimates, though EBITDA margin was higher due to lower operating costs. Revenue in US was below expectation at ~US$63mn due to competitive pressure in sartans and the management indicated the US revenue quarterly base would be between US$55-60mn. Consolidated revenues grew 6.1% YoY to Rs12.8bn (I-Sec: Rs13.1bn), adjusted profit grew 7.6% YoY to Rs2.5bn (I-Sec: Rs2.0bn) and EBITDA margin dropped 40bps YoY to 26.7% (I-Sec: 24.7%). We remain positive on the long-term outlook considering revival in India growth, focus on complex and niche R&D, and track record of healthy return ratios. However, increased competition in sartans and start of new plants would impact earnings growth in medium term. Downgrade to HOLD with a revised target price of Rs984/share.

- India and US were weak; ROW supports growth: India business revenues reported a subdued growth of 4.7% YoY. Segment wise, acute declined 28.8%, specialty grew 21.0% and veterinary grew 55.2%. Sequentially, US revenues declined 7.2% to US$63mn due to increased competitive pressure in sartans. Management expects to launch ~10-15 products in FY22 and continue to launch 15-20 products in the US over the next few years, which would aid growth. RoW business has grown 75.2% YoY on a low base due to cessation of sales caused by serialisation in EU. Sequentially, it grew 36.3% QoQ led by strong order book. API revenue grew strong 38.1% to Rs2.1bn with continued traction in API supplies.

- Lower staff and S,G&A expenses boosted EBITDA: EBITDA margin at 26.7%, declined 110bps sequentially (-40bps YoY), but it was higher than our estimate of 24.7% due to lower staff and S,G&A expenses which declined 10% and 22% QoQ. We expect these costs to increase in the coming quarters as it reverts to pre-COVID levels. While, R&D expenses at 15.2% grew 390bps QoQ, it was flattish YoY. Additional costs related to new plants would restrict EBITDA margin ~23-24% over FY22E-FY23E.

- Outlook: We believe near-term (FY22-23E) earnings performance would be impacted by reducing sales of sartans in US, continuous investments in R&D and additional costs (Rs3-4bn annually) when new plants become operational. However, these costs would be absorbed over the medium term as approvals start resulting in increasing capacity utilization. We expect PAT to decline 9.4% CAGR over FY21-FY23E despite growth of 8.2% CAGR in revenue.

- Valuations and risks: We cut EPS estimates by 3-4% for FY22E-FY23E to factor in lower US sales with declining contribution of sartans. Downgrade the stock to HOLD from ADD with a revised target of Rs984/share (earlier: Rs1,009/share). Key downside risks are: regulatory hurdles and delay in new plant/product approvals. Key upside risks are faster approval of new plants and products.

Shares of ALEMBIC PHARMACEUTICALS LTD. was last trading in BSE at Rs.1006.8 as compared to the previous close of Rs. 983. The total number of shares traded during the day was 65545 in over 3412 trades.

The stock hit an intraday high of Rs. 1034 and intraday low of 982.1. The net turnover during the day was Rs. 65915558.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.


Other Headlines:

KEC International: Company Update - Building on diversification - HDFC Securities

LIC Housing Finance - Q4 FY21 Result Update - YES Securities

Entertainment Network Ltd - Beating on solutions business - ICICI Securities

Asahi India Glass - Operating leverage, product mix aid margins - ICICI Securities

Whirlpool of India - Market leading revenue growth - ICICI Securities

Lemon Tree Hotels - Wait for recovery gets longer - ICICI Securities

LIC Housing Finance - Stupendous growth momentum; needs to shore up provisioning and capital buffer - ICICI Securities

Quant Pick - Bank of Baroda - ICICI Direct

Company Update - Amara Raja Batteries - Investor Event Outcome - ICICI Direct

Q4FY21 Result Update - Bhel - ICICI Direct

Q4FY21 Company Update - NRB Bearings - ICICI Direct

CESC - Q4FY21 First Cut - ICICI Direct

Q4FY21 Result Update - Entertainment Network India - ICICI Direct

LIC Housing Finance Results Review Report - Balance sheet beefs up; P&L to stay soft - HDFC Securities

Jubilant FoodWorks 4QFY21 Results Review Report - Missing excitement; recovery priced in - HDFC Securities

BFSI Sector Update - MFI Consultation Paper Takeaways - Incrementally positive for NBFC-MFIs - HDFC Securities

Q4FY21 Result Update - JK Cement - ICICI Direct

Q4FY21 Result Update - Minda Industries - ICICI Direct

Stock Tales - Indo Count Industries - ICICI Direct

IPO Review - Krishna Institute of Medical Sciences Ltd - ICICI Direct

Q4FY21 Company Update - Greenply Industries - ICICI Direct

IPO Review - Dodla Dairy Ltd - ICICI Direct

Lemon Tree Hotels - Q4FY21 First Cut - ICICI Direct

Jubilant Foodworks - Q4FY21 investor call takeaways - YES Securities

Greenply Industries Ltd - Q4 FY21 Result Update - YES Securities

Whirlpool of India Ltd - Q4 FY21 Result Update - YES Securities

New India Assurance Report - CoRs disappoint yet again - HDFC Securities

Maintain BUY on Kajaria Ceramics - Performance shines through; outlook bright - HDFC Securities

Retain ADD on Deccan Cement - Volume strong; high other expense dents margin - HDFC Securities

Reiterate ADD on NHPC - Lower generation impacts earnings - HDFC Securities

Maintain BUY on JK Cement - Robust volume and utilisation - HDFC Securities

Maintain BUY on DLF - Gaining traction - HDFC Securities

Maintain BUY on Capacite Infraprojects - Marginal miss - HDFC Securities

DLF Ltd - Q4 FY21 Result Update - YES Securities

Greenply Industries Ltd - Q4FY21 first cut - YES Securities

Coal India - Coal makes a comeback - ICICI Securities

Kajaria Ceramics - Q4FY21 beat largely priced in - ICICI Securities

JK Cement - Expansion to drive volume growth - ICICI Securities

Info Edge India - Concerns around Zomato's gig work unwarranted - ICICI Securities

Bharat Heavy Electricals - Higher provisioning impacts margins - ICICI Securities

Mahindra Lifespace Developers - Well poised for growth; initiate with BUY - ICICI Securities

Kajaria Ceramics - Q4FY21 First Cut - ICICI Direct

Gladiator Stocks - Tata Metaliks - ICICI Direct

Q4FY21 Result Update - Gail (India) - ICICI Direct

Q4FY21 Result Update - Engineers India - ICICI Direct

IPO Review - Shyam Metalics & Energy Ltd - ICICI Direct

Coal India - Q4FY21 First Cut - ICICI Direct

Capacite Infraprojects - Q4 FY21 results first cut: Robust performance - YES Securities

Cochin Shipyard - Q4 FY21 results first cut: Strong performance - YES Securities

CARE Ratings - Q4 FY21 results first cut: Stellar Performance - YES Securities


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020